טוען...
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
BACKGROUND: Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr. OBJECTIVE: To analyze long-term safety with sunitinib in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from...
שמור ב:
| הוצא לאור ב: | Eur Urol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5032140/ https://ncbi.nlm.nih.gov/pubmed/26215605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.07.006 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|